ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients
Today three-year follow-up results from Part 1 of the Phase 3 CheckMate -227 trial have…
